Beam Therapeutics (BEAM) Income towards Parent Company (2019 - 2025)
Historic Income towards Parent Company for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to -$112.7 million.
- Beam Therapeutics' Income towards Parent Company fell 1661.36% to -$112.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$414.9 million, marking a year-over-year decrease of 20228.73%. This contributed to the annual value of -$376.8 million for FY2024, which is 18424.88% down from last year.
- Beam Therapeutics' Income towards Parent Company amounted to -$112.7 million in Q3 2025, which was down 1661.36% from -$102.3 million recorded in Q2 2025.
- Over the past 5 years, Beam Therapeutics' Income towards Parent Company peaked at $142.8 million during Q4 2023, and registered a low of -$200.4 million during Q1 2021.
- For the 5-year period, Beam Therapeutics' Income towards Parent Company averaged around -$76.3 million, with its median value being -$89.0 million (2023).
- Its Income towards Parent Company has fluctuated over the past 5 years, first plummeted by 62193.24% in 2021, then surged by 47227.31% in 2023.
- Over the past 5 years, Beam Therapeutics' Income towards Parent Company (Quarter) stood at -$64.7 million in 2021, then surged by 40.73% to -$38.3 million in 2022, then skyrocketed by 472.27% to $142.8 million in 2023, then crashed by 163.33% to -$90.4 million in 2024, then dropped by 24.68% to -$112.7 million in 2025.
- Its last three reported values are -$112.7 million in Q3 2025, -$102.3 million for Q2 2025, and -$109.4 million during Q1 2025.